Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by saltajaon Jan 23, 2016 8:40pm
329 Views
Post# 24487767

RE:RE:RE:PLI next quarter guesses?

RE:RE:RE:PLI next quarter guesses?SeeHorse, with all due respect and in my opinion you have missed the point of investing in PLI if you are concerned about Q1 2016 revenues from the resin/bioseparation business.

In the adsence of a partnership deal with cash PLI will have revenues of 3, 4 if we are lucky 5 million in Q1. If it comes in at 1 mil or 5 mil who cares. We know the business is lumpy. At 20 million annually that business is worth likely less than 20 cent per share. Clearly a small part of what is currently driving the share price.

The market will react to advancements in their drugs in clinical trials and partnerships that will help advance the drugs without dilution.

Buy when you think is right. Insiders seem to think that is now. If this goes back to $1.90 it will be based on wider market conditions and expectations of how far out drug advancement and partnerhsips are, not Q1 rev.

IMHO
Bullboard Posts